menu search

FLGT / Fulgent Genetics, Inc. (FLGT) Q3 2023 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q3 2023 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2023 Earnings Call Transcript November 3, 2023 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - CEO Brandon Perthuis - CCO Paul Kim - CFO Lawrence Weiss - Chief Medical Officer Conference Call Participants David Westenberg - Piper Sandler Andrew Cooper - Raymond James Operator Hello, and welcome to the Fulgent Genetics Q3 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation. Read More
Posted: Nov 3 2023, 12:22
Author Name: Seeking Alpha
Views: 062312

FLGT News  

Fulgent Genetics, Inc. (FLGT) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 3, 2023

Fulgent Genetics, Inc. (FLGT) Q3 2023 Earnings Call Transcript

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2023 Earnings Call Transcript November 3, 2023 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsie more_horizontal

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 4, 2023

Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares more_horizontal

Fulgent Genetics: Post-Pandemic Devaluing Appears Overdone

By Seeking Alpha
July 29, 2023

Fulgent Genetics: Post-Pandemic Devaluing Appears Overdone

Fulgent Genetics is a technology-driven company focused on clinical diagnostics and therapeutics, with recent expansion into precision medicine. FLGT' more_horizontal

2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years

By The Motley Fool
May 23, 2023

2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years

Certain biotechs that hit it big early during the pandemic are now undervalued. BioNTech is preparing for a rapid pace of new drug launches. more_horizontal

What To Expect From Fulgent Genetics In 2023

By Seeking Alpha
May 14, 2023

What To Expect From Fulgent Genetics In 2023

We initiate our coverage of Fulgent Genetics with an "outperform" rating and a $42 target price for the next 12 months. The company is continuing its more_horizontal

Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?

By Zacks Investment Research
May 8, 2023

Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?

Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year. more_horizontal

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 5, 2023

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares more_horizontal

Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?

By Zacks Investment Research
April 12, 2023

Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?

Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year. more_horizontal


Search within

Pages Search Results: